Skip to main content
H.R. 890 119th Congress House

Stopping Pharma’s Ripoffs and Drug Savings For All Act

Official title: To amend title 35, United States Code, to prevent double patenting, and for other purposes.

Introduced: January 31, 2025 Introduced by: Patrick Ryan Democratic · New York See on congress.gov
Commerce
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 31, 2025
Referred to the House Committee on the Judiciary.
Jan 31, 2025
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now January 31, 2025

Referred to the House Committee on the Judiciary.

 Plain-English summary Congressional Research Service

Stopping Pharma’s Ripoffs and Drug Savings For All Act

This bill addresses double patenting with respect to drug-related patents. Specifically, the bill requires an owner of drug-related patents, if the owner lists more than one patent as covering a particular drug, to prove in certain proceedings that each patent covers a distinct invention. If the patent owner fails to do so, then the owner shall have disclaimed patent protection from all the listed patents after the first patent expires.

This requirement shall apply to various proceedings challenging the validity of drug-related patents, as well as to infringement lawsuits filed by the patent owner against companies seeking Food and Drug Administration approval for generic or biosimilar versions of patented drugs.

The bill also directs the U.S. Patent and Trademark Office (USPTO) to review its examination procedures to prevent granting multiple patents for the same drug or biological product, unless the patents cover distinct inventions. The USPTO shall report to Congress its findings and recommendations from the review.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 23

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 23 filings →
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 890: Stopping Pharma’s Ripoffs and Drug Savings For All Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-890/
MLA
"H.R. 890: Stopping Pharma’s Ripoffs and Drug Savings For All Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-890/.
Bluebook (legal)
H.R. 890, 119th Cong. (2026), https://openamerica.io/bill/119-HR-890/.
Markdown link
[H.R. 890: Stopping Pharma’s Ripoffs and Drug Savings For All Act](https://openamerica.io/bill/119-HR-890/)
Report a problem